论文部分内容阅读
目的:探讨多巴丝肼联合普拉克索治疗帕金森病的临床疗效。方法:以入院病历号为编号,根据随机数字表,将106名帕金森病患者随机分成分两组,每组53例。治疗过程中,给予多巴丝肼片治疗的患者记为对照组(53例);给予多巴丝肼联合普拉克索治疗的患者记为观察组(53例)。连续治疗12周,观察两组患者总疗效、UPDRS评分、HAMD评分及不良反应,探讨其临床治疗价值。结果:1观察组总有效率明显高于对照组总有效率,差异有统计学意义(P<0.05)。2与治疗前相比,治疗后两组UPDRS各项评分均明显改善(P<0.05),且观察组UPDRS各项评分明显优于对照组(P<0.05)。3与治疗前相比,治疗后两组HAMD评分均明显改善(P<0.05),且观察组HAMD评分明显优于对照组(P<0.05)。结论:多巴丝肼联合普拉克索治疗帕金森病疗效确切,安全可靠,值得临床推广应用。
Objective: To investigate the clinical efficacy of dopplerizine combined with pramipexole in the treatment of Parkinson’s disease. Methods: Based on the number of admission medical records, 106 patients with Parkinson’s disease were randomly divided into two groups according to a random number table, with 53 patients in each group. In the course of treatment, patients treated with dopprous hydrazine tablets were recorded as control group (n = 53); patients given dopprous hydrazine combined with pramipexole were recorded as observation group (n = 53). Continuous treatment for 12 weeks, the two groups were observed total efficacy, UPDRS score, HAMD score and adverse reactions, to explore the clinical value. Results: 1 The total effective rate of the observation group was significantly higher than that of the control group, the difference was statistically significant (P <0.05). Compared with those before treatment, UPDRS scores of both groups were significantly improved (P <0.05), and the score of UPDRS in the observation group was significantly better than that of the control group (P <0.05). Compared with before treatment, the HAMD scores of both groups were significantly improved (P <0.05), and the HAMD score of the observation group was significantly better than that of the control group (P <0.05). Conclusion: The combination of dopplerizine and pramipexole in the treatment of Parkinson’s disease is effective, safe and reliable, and is worthy of clinical application.